Recombinant human interferon-beta (Hu-IFN-beta) produced in E. coli.
Conjugate
Unconjugated
Form
Liquid
Storage buffer
whole serum diluted in PBS
Contains
no preservative
Storage Conditions
-20°C
Tested Applications
Dilution *
ELISA (ELISA)
Assay Dependent
Immunohistochemistry (IHC)
Assay Dependent
Immunoprecipitation (IP)
Assay Dependent
Neutralization (Neu)
Assay Dependent
Western Blot (WB)
Assay Dependent
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Background/Target Information
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by "Natural IFN-producing cells" (IPCs) as part of the host immune response and can also inhibit the development of tumors. IFN-beta binding by its receptor results in the activation of the tyrosine kinases Jak1 and Tyk2 and phosphorylation of members of the STAT family of transcription factors, leading to the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
原厂资料：
注意事项：
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
